COMMUNIQUÉS West-GlobeNewswire

Essilor - Communiqué : La dynamique s'amplifie / Chiffre d'affaires 9 mois : + 6,6 % hors change

24/10/2017 - 06:30

La dynamique s'amplifie Chiffre d'affaires 9 mois : + 6,6 % hors change Version PDF du communiqué Accélération de la division « Verres et matériel optique » hors effets des catastrophes naturelles Bonnes performances [...]

Essilor - News Release: Gathering Momentum / Nine-month consolidated revenue up 6.6% in constant currency

24/10/2017 - 06:30

Gathering Momentum Nine-month consolidated revenue up 6.6% in constant currency PDF Version of the news release Growth picking up for Lenses & Optical Instruments excluding the impact of natural disasters New [...]

Telix Pharmaceuticals and ANMI Partner for Prostate Cancer Imaging

24/10/2017 - 01:00

MELBOURNE, Australia and LIÈGE, Belgium, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited ( Telix, Company ), a clinical-stage biopharmaceutical company focused on the development of diagnostic and [...]

Telix Pharmaceuticals Limited Launches $50 Million Underwritten Initial Public Offering (ASX: TLX)

23/10/2017 - 23:00

MELBOURNE, Australia, Oct. 23, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited ( Telix , the Company ), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products [...]

uniQure Announces Proposed Public Offering

23/10/2017 - 22:08

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 23, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical [...]

SPINEWAY : 1er semestre 2017 forte progression des résultats. Chiffre d'affaires à 9 mois 2017 7,4 M€ (+ 125%).

23/10/2017 - 18:30

Communiqué de presse Ecully, le 23 octobre 2017 1 er semestre 2017 : Forte progression des résultats semestriels Amélioration du BFR Chiffre d'affaires à 9 mois de 7,4 M€ (+ 125%) En Milliers d'euros 30/06/16 30/06/17 [...]

SPINEWAY : Sharp increase for 2017 half-year results. 2017 nine-month sales revenue of €7.4M (+125%)

23/10/2017 - 18:30

Press release Ecully, 23 October 2017 1 st half of 2017: Sharp increase in half-year results Improved WCR Nine-month sales revenue of €7.4M (+125%) In thousands of euros 30 June 2016 30 June 2017 Sales revenue 2 443 6 [...]

Ossur Hf : Transactions in relation to share buyback program

23/10/2017 - 18:00

Announcement from Össur hf. No. 75/2017 Reykjavík, 23 October 2017 On 15 August 2017, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2017. The purpose of the share buyback program is to [...]

Curetis initiates U.S. FDA study for Unyvero Invasive Joint Infections Cartridge

23/10/2017 - 15:01

Curetis initiates U.S. FDA study for Unyvero Invasive Joint Infections Cartridge Initial patient samples collected for second U.S. Unyvero Product Study Prospective clinical trial expected to start in 2018 Amsterdam, [...]

First Patient Treated in Landmark Transcatheter Mitral Valve Replacement (TMVR) Pivotal Trial

23/10/2017 - 15:00

Global Medtronic APOLLO Trial Now Underway with the Intrepid(TM) TMVR System for Patients with Severe Mitral Regurgitation DUBLIN - October 23, 2017 - Medtronic plc (NYSE:MDT) today announced the first patient implant [...]

Summit Therapeutics plc : Block listing application

23/10/2017 - 13:45

Summit Therapeutics plc ("Summit" or the "Company") BLOCK LISTING APPLICATION Oxford, UK, 23 October 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing [...]

Genedrive PLC: genedrive launches Genedrive® Hepatitis C test in Africa

23/10/2017 - 13:00

genedrive plc ("genedrive" or the "Company") genedrive launches Genedrive® Hepatitis C test in Africa Genedrive® HCV ID Kit to be launched at IFCC WorldLab 2017 Congress genedrive plc (AIM: GDR), the near patient [...]

Rapid Micro Biosystems Awarded a Contract by Biomedical Advanced Research and Development Authority (BARDA) for the Implementation of a Rapid Sterility Test for Vaccines

23/10/2017 - 13:00

LOWELL, Mass., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, a leading provider of automated, non-destructive, rapid microbial detection, is pleased to announce the receipt of a $7.3 million contract from [...]

Shire to Present New Data to Help Advance Understanding of Rare Diseases

23/10/2017 - 13:00

Shire to Present New Data to Help Advance Understanding of Rare Diseases Research to be presented at ACAAI 2017 Annual Scientific Meeting, reinforcing Shire's commitment to help patients living with hereditary [...]

Novo Nordisk A/S - Share repurchase programme

23/10/2017 - 12:55

Bagsværd, Denmark, 23 October 2017 - On 2 February 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April [...]

Vistin Pharma ASA : Invitation to presentation of Q3 2017 results

23/10/2017 - 09:28

Oslo, 23 October 2017 Vistin Pharma ASA (OSE: VISTIN), a producer of high quality API's for the international pharmaceutical industry, will release its third quarter 2017 results on Friday 27 October 2017. The results [...]

NANOBIOTIX annonce avoir terminé l'inclusion des patients dans l'essai de phase II/III de NBTXR3 dans les Sarcome des Tissus Mous

23/10/2017 - 08:00

Nanobiotix annonce avoir terminé l'inclusion des patients dans l'essai de phase II/III de NBTXR3 dans les Sarcome des Tissus Mous Paris, France, et Cambridge, Massachusetts, USA, 23 octobre 2017 - NANOBIOTIX (Euronext: [...]

NANOBIOTIX completes patient inclusion for Phase II/III trial of NBTXR3 in soft tissue sarcoma

23/10/2017 - 08:00

Nanobiotix completes patient inclusion for Phase II/III trial of NBTXR3 in soft tissue sarcoma Paris, France and Cambridge, Massachusetts, USA, October 23, 2017 - NANOBIOTIX NANOBIOTIX (Euronext: NANO - ISIN: [...]

Ergomed's first-in-class haemostat, PeproStat(TM), reports positive top-line results and meets key endpoints in Phase II study

23/10/2017 - 08:00

PRESS RELEASE Ergomed's first-in-class haemostat, PeproStat(TM), reports positive top-line results and meets key endpoints in Phase II study Highly innovative blood free haemostat met the primary efficacy endpoint of [...]